Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Seeking Alpha
Its pipeline includes promising drugs like IMVT-1402, despite some clinical risks. Financially, Roivant is well-capitalized with $6.67 billion in cash against minimal liabilities. Investment recommendation: Buy Roivant as part of a high-risk segment of a diversified portfolio. Roivant Sciences: Strategic Moves and Diverse Pipeline Roivant Sciences NASDAQ: ROIV ) is down nearly 5% since my last update in September. Back then, I highlighted the company's strong balance sheet and opportunity in dermatology. Roivant has been quite busy recently. Earlier Recommended For You Recommended For You About ROIV Stock
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]Yahoo! Finance
- Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisBusiness Wire
- OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/30/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- ROIV's page on the SEC website